BTIG analyst David Larsen raised the firm’s price target on Evolent Health (EVH) to $45 from $40 and keeps a Buy rating on the shares. The company’s Q4 results were "excellent", with higher than expected revenue and adjusted EBITDA, the analyst tells investors in a research note. BTIG adds that it is positive on Evolent’s Humana (HUM) relationship and the "massive in-sell potential" into Humana for over 30 additional states.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EVH:
- Evolent Health sees Q1 revenue $420M-$440M, consensus $410.36M
- Evolent Health sees FY23 revenue $1.92B-$1.96B, consensus $1.76B
- Evolent Health Announces Fourth Quarter and Full Year 2022 Results
- Evolent Health reports Q4 adjusted EPS 10c, consensus 16c
- Evolent Health price target raised to $59 from $57 at Cowen